Detalles de la búsqueda
1.
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
N Engl J Med
; 363(14): 1303-12, 2010 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20879879
2.
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Br J Clin Pharmacol
; 76(1): 78-88, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23190017
3.
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Arthritis Rheum
; 63(2): 337-45, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21279990
4.
JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
J Immunol
; 183(3): 2183-92, 2009 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19596999
5.
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.
Drug Metab Dispos
; 38(7): 1166-76, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20371637
6.
Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing.
Birth Defects Res A Clin Mol Teratol
; 85(2): 130-6, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19107952
7.
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Drugs R D
; 16(1): 81-92, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26739683
8.
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
J Rheumatol
; 40(4): 369-78, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23378467
9.
Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
J Clin Pharmacol
; 51(9): 1310-8, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21209239
10.
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
J Cancer Res Clin Oncol
; 136(1): 99-113, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19609559
11.
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Arthritis Rheum
; 58(11): 3309-18, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18975322
12.
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Arthritis Rheum
; 58(5): 1433-44, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18438845
13.
Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.
Toxicol Appl Pharmacol
; 221(3): 268-77, 2007 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17490694
14.
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Clin Immunol
; 124(3): 244-57, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17537677
15.
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
J Pharmacol Exp Ther
; 319(3): 998-1008, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16946104
16.
An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment.
J Allergy Clin Immunol
; 115(4): 791-6, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15806000
17.
Targeting Syk as a treatment for allergic and autoimmune disorders.
Expert Opin Investig Drugs
; 13(7): 743-62, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15212616
Resultados
1 -
17
de 17
1
Próxima >
>>